Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12015-020-10004-x http://scihub22266oqcxt.onion/10.1007/s12015-020-10004-x 32696426!7372209!32696426     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Stem+Cell+Rev+Rep 2021 ; 17 (1): 63-70 Nephropedia Template TP {{tp|p=32696426|t=2021. Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy |pdf=|usr=}}{{32696426}} gab.com Text Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy JO: Stem Cell Rev Rep http://www.kidney.de/pget.php?&tw=1&pmid=32696426 #FOAvip Nearly 500'000 fatalities due to COVID-19 have been reported globally and the death toll is still rising. Most deaths are due to acute respiratory distress syndrome (ARDS), as a result of an excessive immune response and a cytokine storm elicited by severe SARS-CoV-2 lung infection, rather than by a direct cytopathic effect of the virus. In the most severe forms of the disease therapies should aim primarily at dampening the uncontrolled inflammatory/immune response responsible for most fatalities. Pharmacological agents - antiviral and anti-inflammatory molecules - have not been able so far to achieve compelling results for the control of severe COVID-19 pneumonia. Cells derived from the placenta and/or fetal membranes, in particular amniotic epithelial cells (AEC) and decidual stromal cells (DSC), have established, well-characterized, potent anti-inflammatory and immune-modulatory properties that make them attractive candidates for a cell-based therapy of COVID19 pneumonia. Placenta-derived cells are easy to procure from a perennial source and pose minimal ethical issues for their utilization. In view of the existing clinical evidence for the innocuousness and efficiency of systemic administration of DSCs or AECs in similar conditions, we advocate for the initiation of clinical trials using this strategy in the treatment of severe COVID-19 disease. Twit Text FOAVip Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy ????Stem Cell Rev Rep http://www.kidney.de/pget.php?&tw=1&pmid=32696426 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32696426 #FOAvip English Wikipedia <ref>{{Cite pmid|32696426}}</ref> Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy #MMPMID32696426 Berishvili E; Kaiser L; Cohen M; Berney T; Scholz H; Floisand Y; Mattsson J Stem Cell Rev Rep 2021[Feb]; 17 (1): 63-70 PMID32696426show ga Nearly 500'000 fatalities due to COVID-19 have been reported globally and the death toll is still rising. Most deaths are due to acute respiratory distress syndrome (ARDS), as a result of an excessive immune response and a cytokine storm elicited by severe SARS-CoV-2 lung infection, rather than by a direct cytopathic effect of the virus. In the most severe forms of the disease therapies should aim primarily at dampening the uncontrolled inflammatory/immune response responsible for most fatalities. Pharmacological agents - antiviral and anti-inflammatory molecules - have not been able so far to achieve compelling results for the control of severe COVID-19 pneumonia. Cells derived from the placenta and/or fetal membranes, in particular amniotic epithelial cells (AEC) and decidual stromal cells (DSC), have established, well-characterized, potent anti-inflammatory and immune-modulatory properties that make them attractive candidates for a cell-based therapy of COVID19 pneumonia. Placenta-derived cells are easy to procure from a perennial source and pose minimal ethical issues for their utilization. In view of the existing clinical evidence for the innocuousness and efficiency of systemic administration of DSCs or AECs in similar conditions, we advocate for the initiation of clinical trials using this strategy in the treatment of severe COVID-19 disease. |*Cell- and Tissue-Based Therapy[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19/complications/epidemiology/*therapy/virology[MESH] |Clinical Trials as Topic[MESH] |Cytokine Release Syndrome/complications/epidemiology/pathology/*therapy[MESH] |Cytokines/metabolism[MESH] |Female[MESH] |Humans[MESH] |Lung/drug effects/pathology[MESH] |Placenta/chemistry[MESH] |Pneumonia/complications/epidemiology/*therapy/virology[MESH]Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Th(epmc).pdf DeepDyve Pubget Overpricing